Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ono to Test Pancreatitis Med Foipan for COVID-19: President
May 13, 2020
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
- Xofluza Sees Sharp Sales Decline, but Inavir Logs Growth: 2019-2020 Flu Drug Market
May 13, 2020
- Keytruda Keeps Top Spot in April Drug Ranking: Encise
May 12, 2020
- Shionogi Suffers Lower Earnings as Xofluza Sales Dive 98.4% in FY2019
May 12, 2020
- Santen Snaps Up Exclusive Rights for US Biotech’s Eye Cell Therapy in Japan, Asia, Europe
May 12, 2020
- Daiichi Sankyo Chairman Nakayama to Step Aside as Adviser
May 12, 2020
- Mylan EPD Curbing Nesp Biosimilar Supplies amid Big Demand
May 11, 2020
- Novartis Offers Free Access Program for Zolgensma Diagnostic
May 11, 2020
- Jitsubo Licenses Peptide Manufacturing Technology to Bachem
May 11, 2020
- Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
- Chugai Begins Joint Research with Singapore Agency on Novel Antibody Drug for COVID-19
May 11, 2020
- 4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
May 11, 2020
- Astellas to Carry on Teleworking through End of May
May 11, 2020
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
- Daiichi Sankyo Seeks Gastric Cancer Use for Enhertu
May 8, 2020
- Sales Rep Promotions Decrease 34%, Seminars Down 84%: Intage
May 8, 2020
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
- Takeda to Maintain Partial Voluntary Ban on Sales Reps Activities in Japan amid Coronavirus Woes
May 8, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…